Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR and PEAR-2))

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

C. Pepine, E. Handberg, R. Cooper-DeHoff, et al.. (2003). JAMA. Cited 1,213 times. https://doi.org/10.1001/JAMA.290.21.2805

Loci influencing blood pressure identified using a cardiovascular gene-centric array.

S. Ganesh, V. Tragante, Wei Guo, et al.. (2013). Human molecular genetics. Cited 145 times. https://doi.org/10.1093/hmg/dds555

Loci influencing blood pressure identified using a cardiovascular gene-centric array.

S. Ganesh, V. Tragante, Wei Guo, et al.. (2013). Human molecular genetics. Cited 145 times. https://doi.org/10.1093/hmg/dds555

Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension.

C. Pepine, E. Handberg-Thurmond, R. Marks, et al.. (1998). Journal of the American College of Cardiology. Cited 141 times. https://doi.org/10.1016/S0735-1097(98)00423-9

Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.

Julie A. Johnson, E. Boerwinkle, I. Zineh, et al.. (2009). American heart journal. Cited 136 times. https://doi.org/10.1016/j.ahj.2008.11.018

β‐Adrenergic Receptor Gene Polymorphisms and β‐Blocker Treatment Outcomes in Hypertension

MA Pacanowski, Y. Gong, R. Cooper‐DeHoff, et al.. (2008). Clinical Pharmacology & Therapeutics. Cited 130 times. https://doi.org/10.1038/clpt.2008.139

Genetic Variation in PEAR1 Is Associated With Platelet Aggregation and Cardiovascular Outcomes

J. Lewis, K. Ryan, J. O’Connell, et al.. (2013). Circulation: Cardiovascular Genetics. Cited 101 times. https://doi.org/10.1161/CIRCGENETICS.111.964627

Impact of CYP2D6 polymorphisms on clinical efficacy & tolerability of metoprolol tartrate

Issam S. Hamadeh, T. Langaee, Ruti Dwivedi, et al.. (2014). Clinical pharmacology and therapeutics. Cited 98 times. https://doi.org/10.1038/clpt.2014.62

Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics

C. McDonough, S. E. Burbage, Julio D. Duarte, et al.. (2013). Journal of Hypertension. Cited 73 times. https://doi.org/10.1097/HJH.0b013e32835e2a71

Pharmacometabolomics Reveals Racial Differences in Response to Atenolol Treatment

W. R. Wikoff, R. Frye, Hongjie Zhu, et al.. (2013). PLoS ONE. Cited 73 times. https://doi.org/10.1371/journal.pone.0057639

KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST)

A. Beitelshees, Y. Gong, Danxin Wang, et al.. (2007). Pharmacogenetics and Genomics. Cited 73 times. https://doi.org/10.1097/FPC.0b013e32810f2e3c

Cholesteryl Ester Transfer Protein (CETP) Polymorphisms Affect mRNA Splicing, HDL Levels, and Sex-Dependent Cardiovascular Risk

A. Papp, J. Pinsonneault, Danxin Wang, et al.. (2012). PLoS ONE. Cited 72 times. https://doi.org/10.1371/journal.pone.0031930

CACNA1C Gene Polymorphisms, Cardiovascular Disease Outcomes, and Treatment Response

A. Beitelshees, Hrishikesh Navare, Danxin Wang, et al.. (2009). Circulation: Cardiovascular Genetics. Cited 71 times. https://doi.org/10.1161/CIRCGENETICS.109.857839

Hypertension Susceptibility Loci and Blood Pressure Response to Antihypertensives: Results From the Pharmacogenomic Evaluation of Antihypertensive Responses Study

Y. Gong, C. McDonough, Zhiying Wang, et al.. (2012). Circulation: Cardiovascular Genetics. Cited 70 times. https://doi.org/10.1161/CIRCGENETICS.112.964080

Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated With Antihypertensive Medications

R. Cooper-DeHoff, Sheron Wen, A. Beitelshees, et al.. (2010). Hypertension. Cited 70 times. https://doi.org/10.1161/HYPERTENSIONAHA.109.139592

Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis.

K. Chan, Riyaz S. Patel, P. Newcombe, et al.. (2013). Journal of the American College of Cardiology. Cited 65 times. https://doi.org/10.1016/j.jacc.2012.10.051

G protein receptor kinase 4 polymorphisms: &bgr;-Blocker Pharmacogenetics and treatment-related outcomes in Hypertension

A. Vandell, M. Lobmeyer, Brian E. Gawronski, et al.. (2012). Hypertension. Cited 64 times. https://doi.org/10.1161/HYPERTENSIONAHA.112.198721

G protein receptor kinase 4 polymorphisms: &bgr;-Blocker Pharmacogenetics and treatment-related outcomes in Hypertension

A. Vandell, M. Lobmeyer, Brian E. Gawronski, et al.. (2012). Hypertension. Cited 64 times. https://doi.org/10.1161/HYPERTENSIONAHA.112.198721

Advancing management of hypertension through pharmacogenomics

Julie A. Johnson. (2012). Annals of Medicine. Cited 58 times. https://doi.org/10.3109/07853890.2011.653399

Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES).

T. Gerhard, Y. Gong, A. Beitelshees, et al.. (2008). American heart journal. Cited 53 times. https://doi.org/10.1016/j.ahj.2008.03.007

Association of Chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression

Julio D. Duarte, S. Turner, B. Tran, et al.. (2012). The pharmacogenomics journal. Cited 50 times. https://doi.org/10.1038/tpj.2012.4

Promoter Polymorphisms in ACE (Angiotensin I–Converting Enzyme) Associated With Clinical Outcomes in Hypertension

Andrew D. Johnson, Yan Gong, Danxin Wang, et al.. (2009). Clinical Pharmacology & Therapeutics. Cited 42 times. https://doi.org/10.1038/clpt.2008.194

Genetic Variation in the &bgr;2 Subunit of the Voltage-Gated Calcium Channel and Pharmacogenetic Association With Adverse Cardiovascular Outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES)

Yuxin Niu, Y. Gong, T. Langaee, et al.. (2010). Circulation: Cardiovascular Genetics. Cited 42 times. https://doi.org/10.1161/CIRCGENETICS.110.957654

Large‐Scale Gene‐Centric Analysis Identifies Polymorphisms for Resistant Hypertension

V. Fontana, C. McDonough, Y. Gong, et al.. (2014). Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. Cited 39 times. https://doi.org/10.1161/JAHA.114.001398

Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans

Jorge L. Del-Aguila, A. Beitelshees, R. Cooper-DeHoff, et al.. (2013). The Pharmacogenomics Journal. Cited 36 times. https://doi.org/10.1038/tpj.2013.3

Lack of Correlation Between Thiazide‐Induced Hyperglycemia and Hypokalemia: Subgroup Analysis of Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study

Steven M. Smith, Shawn D. Anderson, Sheron Wen, et al.. (2009). Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Cited 36 times. https://doi.org/10.1592/phco.29.10.1157

Pharmacogenomic Association of Nonsynonymous SNPs in SIGLEC12, A1BG, and the Selectin Region and Cardiovascular Outcomes

C. McDonough, Y. Gong, S. Padmanabhan, et al.. (2013). Hypertension. Cited 34 times. https://doi.org/10.1161/HYPERTENSIONAHA.111.00823

Pharmacogenomic Association of Nonsynonymous SNPs in SIGLEC12, A1BG, and the Selectin Region and Cardiovascular Outcomes

C. McDonough, Y. Gong, S. Padmanabhan, et al.. (2013). Hypertension. Cited 34 times. https://doi.org/10.1161/HYPERTENSIONAHA.111.00823

Urate Transporter Gene SLC22A12 Polymorphisms Associated with Obesity and Metabolic Syndrome in Caucasians with Hypertension

Mohamed Shafiu, Richard J. Johnson, S. Turner, et al.. (2012). Kidney and Blood Pressure Research. Cited 32 times. https://doi.org/10.1159/000337370

Chromosome 9p21 Haplotypes and Prognosis in White and Black Patients With Coronary Artery Disease

Y. Gong, A. Beitelshees, R. Cooper-DeHoff, et al.. (2011). Circulation: Cardiovascular Genetics. Cited 32 times. https://doi.org/10.1161/CIRCGENETICS.110.959296

Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide

Julio D. Duarte, I. Zineh, B. Burkley, et al.. (2012). Journal of Translational Medicine. Cited 29 times. https://doi.org/10.1186/1479-5876-10-56

Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy

T. Gerhard, J. A. Delaney, R. Cooper-DeHoff, et al.. (2012). BMC Medical Research Methodology. Cited 24 times. https://doi.org/10.1186/1471-2288-12-119

β-Blocker pharmacogenetics in heart failure

Jaekyu Shin, Julie A. Johnson. (2008). Heart Failure Reviews. Cited 23 times. https://doi.org/10.1007/s10741-008-9094-x

Hydrochlorothiazide and Atenolol Combination Antihypertensive Therapy: Effects of Drug Initiation Order

Julie A. Johnson, Yan Gong, Kent R. Bailey, et al.. (2009). Clinical Pharmacology & Therapeutics. Cited 23 times. https://doi.org/10.1038/clpt.2009.101

Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response

S. Turner, G. Schwartz, A. Chapman, et al.. (2012). Journal of Translational Medicine. Cited 22 times. https://doi.org/10.1186/1479-5876-10-47

Liver X receptor &agr; gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study

Elvin T. Price, M. Pacanowski, Michael A. Martin, et al.. (2011). Pharmacogenetics and Genomics. Cited 21 times. https://doi.org/10.1097/FPC.0b013e3283452fec

Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment

JH Karnes, C. McDonough, Y. Gong, et al.. (2012). The Pharmacogenomics Journal. Cited 20 times. https://doi.org/10.1038/tpj.2012.34

Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment

JH Karnes, C. McDonough, Y. Gong, et al.. (2012). The Pharmacogenomics Journal. Cited 20 times. https://doi.org/10.1038/tpj.2012.34

Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies

M. Solayman, T. Langaee, Y. Gong, et al.. (2019). European Journal of Pharmaceutical Sciences. Cited 18 times. https://doi.org/10.1016/j.ejps.2019.02.013

Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension.

M. Pacanowski, I. Zineh, R. Cooper-DeHoff, et al.. (2009). American journal of hypertension. Cited 17 times. https://doi.org/10.1038/ajh.2009.81

Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β‐Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil‐SR Trandolapril Study) Trials

O. Magvanjav, Y. Gong, C. McDonough, et al.. (2017). Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. Cited 16 times. https://doi.org/10.1161/JAHA.117.006522

Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol.

Steven M. Smith, Y. Gong, S. Turner, et al.. (2012). American journal of hypertension. Cited 15 times. https://doi.org/10.1038/ajh.2011.215

Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes

J. Karnes, Y. Gong, M. Pacanowski, et al.. (2013). Pharmacogenetics and Genomics. Cited 15 times. https://doi.org/10.1097/FPC.0000000000000012

Impact of Genetic Polymorphisms of SLC2A2, SLC2A5, and KHK on Metabolic Phenotypes in Hypertensive Individuals

MyPhuong T. Le, M. Lobmeyer, Marcus Campbell, et al.. (2013). PLoS ONE. Cited 14 times. https://doi.org/10.1371/journal.pone.0052062

Clinical Implementation of Pharmacogenetics: More than One Gene at a Time

J. A. Johnson, T. Klein, M. Relling. (2013). Clinical Pharmacology & Therapeutics. Cited 13 times. https://doi.org/10.1038/clpt.2013.7

Baseline predictors of central aortic blood pressure: a PEAR substudy.

R. Rosenwasser, Niren K. Shah, Steven M. Smith, et al.. (2014). Journal of the American Society of Hypertension : JASH. Cited 13 times. https://doi.org/10.1016/j.jash.2013.12.008

Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study

C. McDonough, N. Gillis, Abdullah Alsultan, et al.. (2013). PLoS ONE. Cited 13 times. https://doi.org/10.1371/journal.pone.0076984

Atenolol Exposure and Risk for Development of Adverse Metabolic Effects: A Pilot Study

Hrishikesh A. Navare, R. Frye, R. Cooper-DeHoff, et al.. (2010). Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Cited 12 times. https://doi.org/10.1592/phco.30.9.872

Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses)

C. McDonough, O. Magvanjav, A. C. Sá, et al.. (2018). Circulation: Genomic and Precision Medicine. Cited 10 times. https://doi.org/10.1161/CIRCGEN.117.001854

Comparison of Office, Ambulatory, and Home Blood Pressure Antihypertensive Response to Atenolol and Hydrochlorthiazide

A. Beitelshees, Y. Gong, K. Bailey, et al.. (2010). The Journal of Clinical Hypertension. Cited 9 times. https://doi.org/10.1111/j.1751-7176.2009.00185.x

Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies

A. C. Sá, A. Webb, Y. Gong, et al.. (2018). BMC Medical Genomics. Cited 9 times. https://doi.org/10.1186/s12920-018-0370-x

Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort

J. Karnes, T. Langaee, C. McDonough, et al.. (2013). Journal of Translational Medicine. Cited 5 times. https://doi.org/10.1186/1479-5876-11-12

Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort

J. Karnes, T. Langaee, C. McDonough, et al.. (2013). Journal of Translational Medicine. Cited 5 times. https://doi.org/10.1186/1479-5876-11-12